Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy. (15th February 2021)

• Record Type: Journal Article
• Authors: Zhou, Yuqi; Maldini, Colby R; Jadlowsky, Julie; Riley, James L
• Is Part Of: Journal of infectious diseases. Volume 223:Number 1(2021)Supplement
• Page Start: S38
• Page End: S45
• Publication Date: 2021-02-15
• Subjects: human-immunodeficiency-virus -- antiretroviral therapy -- latency reversing agent -- T-cell receptor -- chimeric antigen receptor -- T-cell exhaustion -- ex vivo T-cell expansion; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiaa223
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: HIV-infected individuals successfully controlling viral replication via antiretroviral therapy often have a compromised HIV-specific T-cell immune response due to the lack of CD4 T-cell help, viral escape, T-cell exhaustion, and reduction in numbers due to the withdrawal of cognate antigen. A successful HIV cure strategy will likely involve a durable and potent police force that can effectively recognize and eliminate remaining virus that may emerge decades after an individual undergoes an HIV cure regimen. T cells are ideally suited to serve in this role, but given the state of the HIV-specific T-cell response, it is unclear how to best restore HIV-specific T-cell activity prior initiation of a HIV cure strategy. Here, we review several strategies of generating HIV-specific T cells ex vivo that are currently being tested in the clinic and discuss how infused T cells can be part of an HIV cure strategy.